Dyadic International (DYAI) Expected to Announce Quarterly Earnings on Thursday

Dyadic International (NASDAQ:DYAI) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Dyadic International to post earnings of ($0.03) per share and revenue of $1.43 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $0.96 million for the quarter, compared to analysts’ expectations of $1.02 million. Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%. On average, analysts expect Dyadic International to post ($0.15) EPS for the current fiscal year and ($0.08) EPS for the next fiscal year.

Dyadic International Trading Up 12.0%

DYAI stock opened at $0.38 on Tuesday. The stock’s 50 day simple moving average is $0.43 and its 200 day simple moving average is $0.75. Dyadic International has a 12-month low of $0.33 and a 12-month high of $1.60. The stock has a market capitalization of $15.25 million, a PE ratio of -1.65 and a beta of 1.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company focused on developing and commercializing microbial protein-expression technologies for the production of biologic products. Its platforms are designed to enable the efficient development and manufacture of proteins used in vaccines, therapeutics, food and nutrition products, and industrial applications.

The company’s principal technology, the C1 expression platform, is based on a proprietary strain of the fungus Trichoderma reesei.